Withdrawals
| Reasons | 6 Months | 12 Months | 24 Months | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LEF2-150 (n=133) | PL2-150 (n=92) | SSZ2-150 (n=133) | LEF (n=80) | SSZ (n=76) | PL-SSZ2-150 (n=41) | LEF (n=60) | SSZ (n=60) | PL-SSZ (n=26) | |||
| LOE2-150 | 10 (8) | 29 (32) | 14 (11) | 4 (5) | 2 (3) | 2 (5) | 1 (2) | 3 (5) | 3 (12) | ||
| AEs2-150 | 19 (14) | 6 (7) | 25 (19) | 2 (3) | 5 (7) | 9 (22) | 6 (10) | 9 (15) | 1 (4) | ||
| Non-compliance | 5 (4) | 5 (5) | 7 (5) | 2 (3) | 0 (0) | 1 (2) | 3 (5) | 1 (2) | 0 (0) | ||
| Other | 3 (2) | 1 (1) | 4 (3) | 1 (1) | 1 (1) | 0 | 1 (2) | 1 (2) | 1 (4) | ||
| Total | 37 (28) | 41 (45) | 50 (38) | 9 (11) | 8 (11) | 12 (29) | 11 (18) | 14 (23) | 5 (19) | ||
↵2-150 LOE = lack of efficacy; AE = adverse event; LEF = leflunomide; PL = placebo; SSZ = sulfasalazine; PL-SSZ = PL group switched to SSZ at six months.